Description
Reafferon-ES-Lipinte Pharmacodynamics
It has an immunomodulatory and antiviral effect.
Recombinant human interferon alfa-2b, the active ingredient of the drug, is synthesized by the bacterial cells of Escherichia coli strain SG-20050/pIF 16, which have a gene of human interferon alfa-2b built into their genetic apparatus. It is a protein containing 165 amino acids and is identical in its characteristics and properties to human leukocyte interferon alpha-2b.
The antiviral effect of interferon alfa-2b is manifested during the period of virus reproduction by its active incorporation into the metabolic processes of cells. Interferon alfa-2b, interacting with specific receptors on cell surface, initiates a number of intracellular changes, including the synthesis of specific cytokines and enzymes (2-5-adenylate synthetase and protein kinase), the action of which inhibits the formation of viral protein and viral ribonucleic acid in the cell. Immunomodulatory effect of interferon alfa-2b is manifested as an increase of phagocytic activity of macrophages, increase of specific cytotoxic effect of lymphocytes on target cells, changes of quantitative and qualitative composition of secreted cytokines, changes of functional activity of immunocompetent cells, changes of production and secretion of intracellular proteins.
Indications
Complex therapy of patients with acute hepatitis B, chronic hepatitis B in active and non-active replicative forms, and also chronic hepatitis B complicated with glomerulonephritis.
Treatment of patients with atopic diseases, allergic rhinoconjunctivitis, bronchial asthma with specific immunotherapy.
Prevention and treatment of flu and acute respiratory viral infections in adults and children.
Integrated treatment of urogenital chlamydial infection in adults.
Complex therapy of febrile and meningeal forms of tick-borne encephalitis in adults.
Emergency prophylaxis of tick-borne encephalitis in combination with antitick-borne immunoglobulin.
Contraindications
– Hypersensitivity to interferon or any other components of the preparation;
– Severe forms of allergic diseases;
– Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
– Pregnancy and breast-feeding.
Caution:
Hepatic and/or renal failure, marked myelosuppression, thyroid disease.
Dosage and administration
- It is used orally.
- Immediately before use, 1-2 ml of distilled or cooled boiled water is added to the contents of the bottle. When shaking for 1-5 minutes a homogeneous suspension should be formed.
- In acute hepatitis B the drug is taken 30 minutes before the meal according to the following scheme:
– Adults and school-age children – 1 million ME 2 times a day for 10 days;
– For children of preschool age (from 3 to 7 years) – 500,000 ME 1 time per day during 10 days or, after controlling blood chemistry, for a longer time – until complete clinical recovery. - In chronic hepatitis B in active and non-active replicative forms and also in chronic hepatitis B associated with glomerulonephritis, the drug is taken 30 minutes before the meal according to the following regimen:
– adults and school-age children – 1 million ME twice a day for 10 days and then for 1 month – every other day, once a day (at bedtime);
– Children of preschool age (from 3 to 7 years) – 500,000 ME twice a day for 10 days and then – 500,000 ME for 1 month every other day, once a day (at night). - During specific immunotherapy the drug is taken in the morning hours, 30 minutes after meals, according to the following regimen:
– in allergic rhinoconjunctivitis in adults – 500 thousand ME daily for 10 days (course dose of 5 million ME);
– In atopic bronchial asthma in adults – 500,000 ME daily for 10 days and then 500,000 ME every other day for 20 days. The total duration of treatment is 30 days. - During prevention and treatment of flu and acute respiratory viral infections the drug is taken 30 min before the meal:
– For prophylaxis: for adults and children over 15 years old – 500,000 ME once a day twice a week during one month during the period of peak of disease; for children from 3 to 15 years old
– 250,000 ME once a day twice a week for one month during the peak of the disease.
– In therapy of influenza and acute respiratory infections: for adults and children over 15 years old – 500,000 ME daily two times a day for 3 days; for children from 3 to 15 years old – 250,000 ME daily two times a day for 3 days. - In combination therapy of urogenital infections in adults the drug is taken
In combination therapy of urogenital infections in adults the preparation is taken 30 minutes before the meal and 500,000 ME daily twice a day for 10 days. - In complex therapy of tick-borne encephalitis the drug is taken 30 minutes before meals:
– in febrile form: 500 thousand ME twice a day (morning and evening) for 7 days;
– in case of meningeal form: 500,000 ME twice a day (morning and evening) for 10 days; - In case of emergency prophylaxis of tick-borne encephalitis the drug is taken 30 minutes before meals and 500,000 ME twice a day (morning and evening) for 5 days. Antitick-borne immunoglobulin is administered intramuscularly once not later than the 4th day after a tick bite at a dose of 0.1 ml/kg.
